Sunflower Pharmaceutical Group (002737) Fundamentals 2026 — Revenue Analysis | SniperIQ
Sunflower Pharmaceutical Group (002737) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥7.7B, trading at ¥13.21 on the SHZ. This SniperIQ fundamentals page covers Sunflower Pharmaceutical Group's valuation, profitability (net margin -8.2%), revenue (¥2.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sunflower Pharmaceutical Group's market cap?
Sunflower Pharmaceutical Group (002737) has a market capitalization of approximately ¥7.7B, trading at ¥13.21 on the SHZ. Market cap moves with the live share price.
What is Sunflower Pharmaceutical Group's P/E ratio?
Sunflower Pharmaceutical Group's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Sunflower Pharmaceutical Group?
Sunflower Pharmaceutical Group runs a net profit margin of -8.2%, a gross margin of 44.4%, and an operating margin of -8.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Sunflower Pharmaceutical Group generate?
Sunflower Pharmaceutical Group reported revenue of ¥2.3B for fiscal year 2025, with net income of -¥258M and earnings per share (EPS) of -0.44. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Sunflower Pharmaceutical Group pay a dividend?
Sunflower Pharmaceutical Group offers a trailing dividend yield of about 1.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Sunflower Pharmaceutical Group financially healthy?
Sunflower Pharmaceutical Group carries a debt-to-equity ratio of 0.03x and a current ratio of 3.33x, with a market beta of 0.33. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sunflower Pharmaceutical Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sunflower Pharmaceutical Group (002737) the key facts are: market cap ¥7.7B, revenue ¥2.3B, 52-week range 11.04-17.17. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Sunflower Pharmaceutical Group's full fundamentals live
Get Sunflower Pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.